CLRB insider transaction filings
Cellectar Biosciences, Inc. — 25 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-10. Screen CLRB transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-10 | 4/A | Loren Stefan | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Kolean Chad J — CFO | Grant/award (A): 92,000 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Chanan-Khan Asher — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Gu Andrew — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Longcor Jarrod — Chief Operating Officer | Grant/award (A): 118,000 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Swirsky Douglas J — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Loren Stefan | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | CARUSO JAMES V — President & CEO, Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | NEIS JOHN — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | DRISCOLL FREDERICK W — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Longcor Jarrod — Chief Operating Officer | Purchase (P): 8,680 @ $2.88 · Purchase (P): 26,040 (derivative) @ $0.01 | EDGAR |
| 2026-05-11 | 4 | CARUSO JAMES V — Chief Executive Officer, Director | Purchase (P): 8,680 @ $2.88 · Purchase (P): 26,040 (derivative) @ $0.01 | EDGAR |
| 2025-12-16 | 4 | NEIS JOHN — Director | Sale (S): 198 @ $3.70 | EDGAR |
| 2025-07-03 | 4 | Longcor Jarrod — Chief Operating Officer | Purchase (P): 10,000 @ $4.99 · Purchase (P): 10,000 (derivative) @ $0.01 | EDGAR |
| 2025-07-03 | 4 | Kolean Chad J — Chief Financial Officer | Purchase (P): 5,000 @ $4.99 · Purchase (P): 5,000 (derivative) @ $0.01 | EDGAR |
| 2025-07-03 | 4 | CARUSO JAMES V — Chief Executive Officer, Director | Purchase (P): 10,000 @ $4.99 · Purchase (P): 10,000 (derivative) @ $0.01 | EDGAR |
| 2025-03-12 | 4 | Longcor Jarrod — Chief Operating Officer | Purchase (P): 30,000 @ $0.28 | EDGAR |
| 2025-02-18 | 4 | Swirsky Douglas J — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Loren Stefan — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Longcor Jarrod — Chief Operating Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Kolean Chad J — Chief Financial Officer | Grant/award (A): 290,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Chanan-Khan Asher — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | CARUSO JAMES V — President and CEO, Director | Grant/award (A): 900,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | NEIS JOHN — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | DRISCOLL FREDERICK W — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Cellectar Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-06 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CLRB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →